aTyr Pharma launches $50M public offering of 22.2M shares at $2.25; plans Phase 2 SSc-ILD study

aTYR PHARMA INC

Gross proceeds ~$50M from 22,225,000 shares at $2.25; underwriters have 30-day option for 3,333,750 additional shares.
FDA cleared IND for efzofitimod in SSc-ILD; Phase 2 proof-of-concept study planned for 2023.
Phase 2 study: 28-week, randomized, double-blind, placebo-controlled, 2:2:1 dosing 270 mg, 450 mg efzofitimod or placebo; 25 patients.
Orphan drug designations: FDA: sarcoidosis (Jan 2022) and systemic sclerosis (Apr 2022); EU: sarcoidosis (Jan 2023).
Risk factor supplement: no guarantee of orphan drug exclusivity for future indications or jurisdictions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.